Calow et al., 2016 - Google Patents
Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activityCalow et al., 2016
View PDF- Document ID
- 16010594129323864752
- Author
- Calow J
- Behrens A
- Mader S
- Bockau U
- Struwe W
- Harvey D
- Cormann K
- Nowaczyk M
- Loser K
- Schinor D
- Hartmann M
- Crispin M
- Publication year
- Publication venue
- MAbs
External Links
Snippet
Antibody glycosylation is a key parameter in the optimization of antibody therapeutics. Here, we describe the production of the anti-cancer monoclonal antibody rituximab in the unicellular ciliate, Tetrahymena thermophila. The resulting antibody demonstrated …
- 102000004965 antibodies 0 title abstract description 120
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subedi et al. | The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor | |
| Liu et al. | Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation | |
| Yu et al. | Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans | |
| Zhang et al. | Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study | |
| JP6750148B2 (en) | Process for producing sugar chain cleaving antibody and uniform sugar chain antibody | |
| Tada et al. | Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori) | |
| Raymond et al. | Production of α2, 6-sialylated IgG1 in CHO cells | |
| US11421209B2 (en) | Cells producing Fc containing molecules having altered glycosylation patterns and methods and use thereof | |
| Sjögren et al. | On enzymatic remodeling of IgG glycosylation; unique tools with broad applications | |
| Rose et al. | Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG | |
| Calow et al. | Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity | |
| Edwards et al. | Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation | |
| JP2008538926A (en) | Single chain antibody with cleavable linker | |
| CA3192770A1 (en) | Fab sialylation of antibodies | |
| WO2019234021A1 (en) | Glycoengineered monoclonal antibody | |
| WO2014184545A2 (en) | Antibodies | |
| Ha et al. | Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris | |
| Kircheis et al. | Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314 | |
| Bennett et al. | Implementation of glycan remodeling to plant-made therapeutic antibodies | |
| Liu et al. | Evaluation of a glycoengineered monoclonal antibody via LC-MS analysis in combination with multiple enzymatic digestion | |
| Wang et al. | The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions | |
| EP2791164B1 (en) | Non-fucosylated glycoprotein comprising the Fc domain of an antibody | |
| Shenoy et al. | Expression and display of glycoengineered antibodies and antibody fragments with an engineered yeast strain | |
| Egashira et al. | Characterization of glycoengineered anti-HER2 monoclonal antibodies produced by using a silkworm–baculovirus expression system | |
| Simonov et al. | Control of therapeutic IgG antibodies galactosylation during cultivation process and its impact on IgG1/FcγR interaction and ADCC activity |